Supplementary Fig. S.2 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Almohanad A. Alkayyal,Lee‐Hwa Tai,Michael A. Kennedy,Christiano Tanese de Souza,Jiqing Zhang,Charles Lefebvre,Shalini Sahi,Abhirami A. Ananth,Ahmad Bakur Mahmoud,Andrew P. Makrigiannis,Greg O. Cron,Blair MacDonald,E. Celia Marginean,David F. Stojdl,John C. Bell,Rebecca C. Auer

DOI: https://doi.org/10.1158/2326-6066.22538816

2023-01-01

Abstract:Supplementary figure S.2: Viral fitness, kinetics and tumour cytotoxicity.

What problem does this paper attempt to address?

Supplementary Fig. S.2 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Almohanad A. Alkayyal,Lee‐Hwa Tai,Michael A. Kennedy,Christiano Tanese de Souza,Jiqing Zhang,Charles Lefebvre,Shalini Sahi,Abhirami A. Ananth,Ahmad Bakur Mahmoud,Andrew P. Makrigiannis,Greg O. Cron,Blair MacDonald,E. Celia Marginean,David F. Stojdl,John C. Bell,Rebecca C. Auer

DOI: https://doi.org/10.1158/2326-6066.22538816.v1

2023-01-01

Abstract:Supplementary figure S.2: Viral fitness, kinetics and tumour cytotoxicity.
Supplementary Fig. S.6 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Almohanad A. Alkayyal,Lee-Hwa Tai,Michael A. Kennedy,Christiano Tanese de Souza,Jiqing Zhang,Charles Lefebvre,Shalini Sahi,Abhirami A. Ananth,Ahmad Bakur Mahmoud,Andrew P. Makrigiannis,Greg O. Cron,Blair Macdonald,E. Celia Marginean,David F. Stojdl,John C. Bell,Rebecca C. Auer

DOI: https://doi.org/10.1158/2326-6066.22538804.v1

2023-01-01

Abstract:Cytotoxicity of human NK cells derived from healthy individual and cancer patients.
Supplementary Fig. S.5 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Almohanad A. Alkayyal,Lee‐Hwa Tai,Michael A. Kennedy,Christiano Tanese de Souza,Jiqing Zhang,Charles Lefebvre,Shalini Sahi,Abhirami A. Ananth,Ahmad Bakur Mahmoud,Andrew P. Makrigiannis,Greg O. Cron,Blair MacDonald,E. Celia Marginean,David F. Stojdl,John C. Bell,Rebecca C. Auer

DOI: https://doi.org/10.1158/2326-6066.22538807

2023-01-01

Abstract:In vitro comparison of IL-12 expression levels from G-less MRB-IL12-ICV and MG1-IL12-ICV.
Supplementary Fig. S.3 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Almohanad A. Alkayyal,Lee‐Hwa Tai,Michael A. Kennedy,Christiano Tanese de Souza,Jiqing Zhang,Charles Lefebvre,Shalini Sahi,Abhirami A. Ananth,Ahmad Bakur Mahmoud,Andrew P. Makrigiannis,Greg O. Cron,Blair MacDonald,E. Celia Marginean,David F. Stojdl,John C. Bell,Rebecca C. Auer

DOI: https://doi.org/10.1158/2326-6066.22538813

2023-01-01

Abstract:MG1-IL-12-ICV induces systemic NK cell cytokines secretion.
Supplementary Fig. S.7 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Almohanad A. Alkayyal,Lee‐Hwa Tai,Michael A. Kennedy,Christiano Tanese de Souza,Jiqing Zhang,Charles Lefebvre,Shalini Sahi,Abhirami A. Ananth,Ahmad Bakur Mahmoud,Andrew P. Makrigiannis,Greg O. Cron,Blair MacDonald,E. Celia Marginean,David F. Stojdl,John C. Bell,Rebecca C. Auer

DOI: https://doi.org/10.1158/2326-6066.22538801

2023-01-01

Abstract:MG1-IL12-ICV vaccine enhances natural killer cell recruitment and function via dendritic cells.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Jhanelle E. Gray,Andreas Saltos,Tawee Tanvetyanon,Eric B. Haura,Ben Creelan,Scott J. Antonia,Michael Shafique,Hong Zheng,Wenjie Dai,James J. Saller,Zhihua Chen,Nishan Tchekmedyian,Kristen Goas,Ram Thapa,Theresa A. Boyle,Dung-Tsa Chen,Amer A. Beg

DOI: https://doi.org/10.1158/1078-0432.22471758.v1

2023-01-01

Abstract:Approach to assess levels of monocytic and PMN MDSC in patient PBMCs.
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Ли Шен,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22490453.v1

2023-01-01

Abstract:EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494754

2023-01-01

Abstract:IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384260.v1

2023-01-01

Abstract:Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 6 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384251

2023-01-01

Abstract:Supplementary Figure 6 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 2 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384263

2023-01-01

Abstract:Supplementary Figure 2 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384254

2023-01-01

Abstract:Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 7 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384248

2023-01-01

Abstract:Supplementary Figure 7 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384257

2023-01-01

Abstract:Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 1 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384266

2023-01-01

Abstract:Supplementary Figure 1 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells

Magali Terme,Evelyn Ullrich,Laetitia Aymeric,Kathrin Meinhardt,Jérôme D. Coudert,Mélanie Desbois,François Ghiringhelli,Sophie Viaud,Bernard Ryffel,Hideo Yagita,Lieping Chen,Salaheddine Mécheri,Gilles Kaplanski,Armelle Prévost-Blondel,Masashi Kato,Joachim L. Schultze,Eric Tartour,Guido Kroemer,Mariapia Degli-Esposti,Nathalie Chaput,Laurence Zitvogel

DOI: https://doi.org/10.1158/0008-5472.22391028

2023-01-01

Abstract:PDF file - 87K, Kit+ CD11b- NK cells expand in lymphoid organs of mice bearing different types of tumors

Supplementary Fig. S.2 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.2 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.6 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.5 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.3 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.7 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 6 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 7 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 1 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells

Supplementary Fig. S.2 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.2 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.6 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.5 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.3 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Fig. S.7 from NK-Cell Recruitment is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S2 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 6 from Tumor-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 2 from Tumor-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 5 from Tumor-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 7 from Tumor-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 1 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 1 from Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells

Supplementary Figure 6 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 7 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts